NeoVax Meets Nivolumab: Inside a Personalised Vaccine’s First Ovarian Cancer Trial
NeoVax, a vaccine manufactured from each patient's tumour mutations, was combined with nivolumab in a phase 1 ovarian cancer trial. What the technology showed, and what it did not.
